Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure

Table 1 Detectable differences in study endpoints by echocardiographic correlation estimates between baseline measurement and end of intervention (2 years)

Endpoint	Baseline value	Estimated SD	Correlation between measurements
Endpoint	Baseline value	Estimated SD	0.6	0.7	0.8
Primary
LVWT/D (Z-score)	−0.7	1.0	0.35	0.31	0.25
Secondary
LVEDV (ml)	105.7	26.9	9.4	8.4	6.7
LVESV (ml)	45.0	11.7	4.1	3.6	2.9
LVEF (%)	60.0	5.0	1.8	1.6	1.3

Abbreviations: LVWT/D left ventricular wall thickness/dimension ratio, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVEF left ventricular ejection fraction, SD standard deviation

ISSN: 1471-2261